Triplet Therapeutics was formed to develop transformational treatments for patients with repeat expansion disorders (REDs) – a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy type 1, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) – leveraging insights from the human genetics of REDs. Triplet ceased operations in 2022.
| Headquarters | Cambridge, MA |
| Pipeline | Preclinical |
| @TripletThera |